253 related articles for article (PubMed ID: 18343741)
1. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Galles AC; Jones RN; Sader HS
J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
[TBL] [Abstract][Full Text] [Related]
2. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
Wei C; Ni W; Cai X; Cui J
Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
[TBL] [Abstract][Full Text] [Related]
3. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
[No Abstract] [Full Text] [Related]
4. Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Chong SY; Lee K; Chung HS; Hong SG; Suh Y; Chong Y
Microb Drug Resist; 2017 Mar; 23(2):163-168. PubMed ID: 27294684
[TBL] [Abstract][Full Text] [Related]
5. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
Wu H; Wang JT; Shiau YR; Wang HY; Lauderdale TL; Chang SC;
J Microbiol Immunol Infect; 2012 Apr; 45(2):120-6. PubMed ID: 22154599
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
Wei C; Ni W; Cai X; Zhao J; Cui J
PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care centre in Hungary.
Juhász E; Pongrácz J; Iván M; Kristóf K
Acta Microbiol Immunol Hung; 2015 Sep; 62(3):295-305. PubMed ID: 26551572
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB
J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423
[TBL] [Abstract][Full Text] [Related]
10. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
11. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.
Juhász E; Krizsán G; Lengyel G; Grósz G; Pongrácz J; Kristóf K
Ann Clin Microbiol Antimicrob; 2014 Dec; 13():333. PubMed ID: 25551459
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F
Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.
Valdezate S; Vindel A; Loza E; Baquero F; Cantón R
Antimicrob Agents Chemother; 2001 May; 45(5):1581-4. PubMed ID: 11302834
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Samra Z; Rosenberg S; Dan M
J Chemother; 2011 Apr; 23(2):77-9. PubMed ID: 21571622
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020.
Lee YL; Liu CE; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106878. PubMed ID: 37285926
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital.
Chung HS; Hong SG; Lee Y; Kim M; Yong D; Jeong SH; Lee K; Chong Y
Yonsei Med J; 2012 Mar; 53(2):439-41. PubMed ID: 22318836
[TBL] [Abstract][Full Text] [Related]
17. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.
Jia W; Wang J; Xu H; Li G
Int J Environ Res Public Health; 2015 May; 12(5):5177-95. PubMed ID: 25985315
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.
Farrell DJ; Sader HS; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2735-7. PubMed ID: 20368399
[TBL] [Abstract][Full Text] [Related]
20. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
